suramin
Phase 2- Indications
- Autism Spectrum Disorder
Company intelligence / Profile preview
PaxMedica, Inc.
Tarrytown, New York, United Statespaxmedica.com ↗
- Ownership
- Public · PXMD
- Employees
- ~7
- Development stage
- Phase 2
01
Overview
Lead candidate PAX-101 (intravenous suramin) is in Phase 3 clinical trials for autism spectrum disorder. The company is developing treatments for disorders with intractable neurologic symptoms.
- Therapeutic areas
- PsychiatryNeurologyInfectious Diseases
- Modalities
- Anti-purinergic drug therapies (APT)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Research collaboration with PolarMar Health for Phase II clinical trial in autism spectrum disorder for emodin
04
Financials
- Market cap
- $88.4K
- Total revenue
- $0
- Enterprise value
- $-236.1K
Beyond the preview
Go deeper on PaxMedica, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PaxMedica, Inc..